The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved MSD’s anti-programmed death receptor-1 (PD-1) therapy ...

The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, ...

Pfizer PFE said it is withdrawing its sickle-cell drug (“SCD”) drug, Oxbryta from worldwide markets. Merck’s MRK Keytruda ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

The US drug giant said the study did not meet its primary endpoint of overall survival. Also Read: Merck’s Keytruda Secures ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...

The EMA CHMP has recommended approval of MSD’s KEYTRUDA for two gynaecological cancers: endometrial and cervical.

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...